Valsartan (CGP-48933)

Catalog No.S1894

For research use only.

Valsartan (CGP-48933) is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.

Valsartan (CGP-48933) Chemical Structure

CAS No. 137862-53-4

Selleck's Valsartan (CGP-48933) has been cited by 4 Publications

1 Customer Review

Purity & Quality Control

Choose Selective Angiotensin Receptor Inhibitors

Biological Activity

Description Valsartan (CGP-48933) is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.
angiotensin II receptor [1]
In vitro

Valsartan dose-dependently inhibits the vasoconstriction induced by angiotensin II and lowers blood pressure in renin-dependent models of hypertension. Valsartan is at least as effective as ACE inhibitors, diuretics, beta-blockers and calcium antagonists. [1]

In vivo Valsartan results in improved glucose tolerance, reduced fasting blood glucose levels, and reduced serum insulin levels in mice fed a Western diet. Valsartan treatment also blocks Western diet-induced increases in serum levels of the proinflammatory cytokines interferon-gamma and monocyte chemotactic protein 1. Valsartan enhances mitochondrial function and prevents Western diet-induced decreases in glucose-stimulated insulin secretion in the pancreatic islets of mice. Valsartan treatment blocks or attenuates Western diet-induced changes in expression of several key inflammatory signals: interleukin 12p40, interleukin 12p35, tumor necrosis factor-alpha, interferon-gamma, adiponectin, platelet 12-lipoxygenase, collagen 6, inducible NO synthase, and AT1R in isolated adipocytes. [2] Valsartan significantly increases insulin-mediated 2-[3H]deoxy-d-glucose (2-[3H]DG) uptake into skeletal muscle and attenuates the increase in plasma glucose concentration after a glucose load and plasma concentrations of glucose and insulin. Valsartan treatment exaggerates the insulin-induced phosphorylation of IRS-1, the association of IRS-1 with the p85 regulatory subunit of phosphoinositide 3 kinase (PI 3-K), PI 3-K activity, and translocation of GLUT4 to the plasma membrane. Valsartan also reduces tumor necrosis factor-alpha (TNF-alpha) expression and superoxide production in skeletal muscle of KK-Ay mice. [3]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 435.52


CAS No. 137862-53-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05194111 Recruiting Drug: Sacubitril-valsartan|Drug: Valsartan Heart Failure|Heart Dysfunction Virginia Commonwealth University March 9 2022 Phase 1|Phase 2
NCT04735354 Active not recruiting Drug: sacubitril/valsartan Heart Failure Novartis Pharmaceuticals|Novartis October 27 2020 --
NCT04753112 Completed Drug: Sacubitril / Valsartan Oral Tablet [Entresto] Pulmonary Hypertension Germans Trias i Pujol Hospital October 29 2020 Phase 3

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Valsartan (CGP-48933) | Valsartan (CGP-48933) ic50 | Valsartan (CGP-48933) price | Valsartan (CGP-48933) cost | Valsartan (CGP-48933) solubility dmso | Valsartan (CGP-48933) purchase | Valsartan (CGP-48933) manufacturer | Valsartan (CGP-48933) research buy | Valsartan (CGP-48933) order | Valsartan (CGP-48933) mouse | Valsartan (CGP-48933) chemical structure | Valsartan (CGP-48933) mw | Valsartan (CGP-48933) molecular weight | Valsartan (CGP-48933) datasheet | Valsartan (CGP-48933) supplier | Valsartan (CGP-48933) in vitro | Valsartan (CGP-48933) cell line | Valsartan (CGP-48933) concentration | Valsartan (CGP-48933) nmr